{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T15:11:55Z","timestamp":1787238715753,"version":"build-2736575974"},"reference-count":65,"publisher":"Elsevier BV","issue":"19","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,4,5]],"date-time":"2023-04-05T00:00:00Z","timestamp":1680652800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1016\/j.vaccine.2023.04.012","type":"journal-article","created":{"date-parts":[[2023,4,8]],"date-time":"2023-04-08T20:57:44Z","timestamp":1680987464000},"page":"3047-3057","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Immunisation with purified Coxiella burnetii phase I lipopolysaccharide confers partial protection in mice independently of co-administered adenovirus vectored vaccines"],"prefix":"10.1016","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2314-507X","authenticated-orcid":false,"given":"Christina","family":"Dold","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5547-6669","authenticated-orcid":false,"given":"Henderson","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Silva-Reyes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luke","family":"Blackwell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aline","family":"Linder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9078-6734","authenticated-orcid":false,"given":"Kevin","family":"Bewley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerry","family":"Godwin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Fotheringham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sue","family":"Charlton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young Chan","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7361-719X","authenticated-orcid":false,"given":"Andrew J.","family":"Pollard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9712-8080","authenticated-orcid":false,"given":"Christine S.","family":"Rollier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2023.04.012_b0005","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1159\/000357107","article-title":"Coxiella burnetii - pathogenic agent of Q (query) fever","volume":"41","author":"G\u00fcrtler","year":"2014","journal-title":"Transfus Med Hemother"},{"issue":"Pt 1","key":"10.1016\/j.vaccine.2023.04.012_b0010","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1017\/S0031182000081014","article-title":"Q fever (Coxiella burnetii) reservoir in wild brown rat (Rattus norvegicus) populations in the UK","volume":"110","author":"Webster","year":"1995","journal-title":"Parasitology"},{"key":"10.1016\/j.vaccine.2023.04.012_b0015","first-page":"9","article-title":"Comparison of Coxiella burnetii excretion between sheep and goats naturally infected with one cattle-associated genotype","author":"Bauer","year":"2020","journal-title":"Pathogens"},{"key":"10.1016\/j.vaccine.2023.04.012_b0020","unstructured":"Select Agents and Toxins List 2022. https:\/\/www.selectagents.gov\/sat\/list.htm (accessed May 1, 2022)."},{"issue":"47","key":"10.1016\/j.vaccine.2023.04.012_b0025","first-page":"110","article-title":"to 1999 in the South of Spain","volume":"2003","author":"de Alarc\u00f3n","year":"1983","journal-title":"J Infect"},{"key":"10.1016\/j.vaccine.2023.04.012_b0030","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1016\/S0140-6736(82)91341-1","article-title":"Q-fever endocarditis in England and Wales, 1975\u201381","volume":"2","author":"Palmer","year":"1982","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2023.04.012_b0035","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/0002-9343(92)90173-9","article-title":"Epidemiologic features and clinical presentation of acute Q fever in hospitalized patients: 323 French cases","volume":"93","author":"Tissot Dupont","year":"1992","journal-title":"Am J Med"},{"key":"10.1016\/j.vaccine.2023.04.012_b0040","first-page":"1","article-title":"Diagnosis and management of Q fever\u2013United States, 2013: recommendations from CDC and the Q Fever Working Group","volume":"62","author":"Anderson","year":"2013","journal-title":"MMWR Recomm Rep"},{"key":"10.1016\/j.vaccine.2023.04.012_b0045","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1097\/INF.0000000000001211","article-title":"Chronic recurrent multifocal Q fever osteomyelitis in children: an emerging clinical challenge","volume":"35","author":"Francis","year":"2016","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2023.04.012_b0050","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1093\/cid\/cix886","article-title":"Treatment of chronic Q fever: clinical efficacy and toxicity of antibiotic regimens","volume":"66","author":"van Roeden","year":"2018","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2023.04.012_b0055","doi-asserted-by":"crossref","first-page":"20934","DOI":"10.1038\/s41598-020-77343-0","article-title":"Analysis of recombinant proteins for Q fever diagnostics","volume":"10","author":"Miller","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.vaccine.2023.04.012_b0060","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1007\/s00392-007-0522-z","article-title":"Late relapse of Q fever endocarditis","volume":"96","author":"Morguet","year":"2007","journal-title":"Clin Res Cardiol"},{"key":"10.1016\/j.vaccine.2023.04.012_b0065","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1111\/j.1467-842X.2003.tb00415.x","article-title":"An economic evaluation of increased uptake in Q fever vaccination among meat and agricultural industry workers following implementation of the National Q Fever Management Program","volume":"27","author":"Kermode","year":"2003","journal-title":"Aust N Z J Public Health"},{"key":"10.1016\/j.vaccine.2023.04.012_b0070","first-page":"6","article-title":"Frequency of adverse events following Q fever immunisation in young adults","author":"Sellens","year":"2018","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.vaccine.2023.04.012_b0075","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1017\/S0950268800059458","article-title":"Vaccine prophylaxis of abattoir-associated Q fever: eight years\u2019 experience in Australian abattoirs","volume":"104","author":"Marmion","year":"1990","journal-title":"Epidemiol Infect"},{"key":"10.1016\/j.vaccine.2023.04.012_b0080","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1128\/iai.61.4.1251-1258.1993","article-title":"Safety and immunogenicity in human volunteers of a chloroform-methanol residue vaccine for Q fever","volume":"61","author":"Fries","year":"1993","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2023.04.012_b0085","first-page":"74","article-title":"Q fever vaccines: present status and application in man","volume":"267","author":"Kaz\u00e1r","year":"1987","journal-title":"Zentralbl Bakteriol Mikrobiol Hyg A"},{"key":"10.1016\/j.vaccine.2023.04.012_b0090","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/s41541-021-00296-6","article-title":"Contributions of lipopolysaccharide and the type IVB secretion system to Coxiella burnetii vaccine efficacy and reactogenicity","volume":"6","author":"Long","year":"2021","journal-title":"npj Vaccines"},{"key":"10.1016\/j.vaccine.2023.04.012_b0095","article-title":"Soluble antigens derived from Coxiella burnetii elicit protective immunity in three animal models without inducing hypersensitivity","volume":"2","author":"Gregory","year":"2021","journal-title":"Cell Rep Med"},{"key":"10.1016\/j.vaccine.2023.04.012_b0100","doi-asserted-by":"crossref","unstructured":"Samuel JE, Hendrix LR. Laboratory maintenance of Coxiella burnetii. Curr Protoc Microbiol 2009;Chapter 6:Unit 6C.1.","DOI":"10.1002\/9780471729259.mc06c01s15"},{"key":"10.1016\/j.vaccine.2023.04.012_b0105","first-page":"10","article-title":"Q fever vaccine development: current strategies and future considerations","author":"Long","year":"2021","journal-title":"Pathogens"},{"key":"10.1016\/j.vaccine.2023.04.012_b0110","doi-asserted-by":"crossref","first-page":"4909","DOI":"10.4049\/jimmunol.1201622","article-title":"Development of a lipopolysaccharide-targeted peptide mimic vaccine against Q fever","volume":"189","author":"Peng","year":"2012","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2023.04.012_b0115","doi-asserted-by":"crossref","first-page":"8372","DOI":"10.4049\/jimmunol.179.12.8372","article-title":"Mechanisms of vaccine-induced protective immunity against Coxiella burnetii infection in BALB\/c mice","volume":"179","author":"Zhang","year":"2007","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2023.04.012_b0120","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1006922","article-title":"Genetic mechanisms of Coxiella burnetii lipopolysaccharide phase variation","volume":"14","author":"Beare","year":"2018","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.vaccine.2023.04.012_b0125","first-page":"327","article-title":"Protective immunity induced by 67 K outer membrane protein of phase I Coxiella burnetii in mice and guinea pigs","volume":"38","author":"Zhang","year":"1994","journal-title":"Acta Virol"},{"key":"10.1016\/j.vaccine.2023.04.012_b0130","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S0952-7915(99)80016-8","article-title":"Responses of CD8(+) T cells to intracellular bacteria","volume":"11","author":"Harty","year":"1999","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.vaccine.2023.04.012_b0135","doi-asserted-by":"crossref","DOI":"10.1016\/j.jinf.2022.02.032","article-title":"Viral vectors expressing group B meningococcal outer membrane proteins induce strong antibody responses but fail to induce functional bactericidal activity","author":"Marsay","year":"2022","journal-title":"J Infect"},{"key":"10.1016\/j.vaccine.2023.04.012_b0140","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/S0140-6736(20)31604-4","article-title":"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1\/2, single-blind, randomised controlled trial","volume":"396","author":"Folegatti","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2023.04.012_b0145","doi-asserted-by":"crossref","first-page":"4470","DOI":"10.1016\/j.vaccine.2016.07.050","article-title":"Influence of adenovirus and MVA vaccines on the breadth and hierarchy of T cell responses","volume":"34","author":"Rollier","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2023.04.012_b0150","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0140-6736(20)32661-1","article-title":"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK","volume":"397","author":"Voysey","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2023.04.012_b0155","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1056\/NEJMoa2117608","article-title":"Final analysis of efficacy and safety of single-dose Ad26.COV2.S","volume":"386","author":"Sadoff","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2023.04.012_b0160","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1093\/infdis\/jiq037","article-title":"Coxiella burnetii antigen-stimulated dendritic cells mediated protection against Coxiella burnetii in BALB\/c mice","volume":"203","author":"Wei","year":"2011","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2023.04.012_b0165","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/1471-2180-12-35","article-title":"Potential serodiagnostic markers for Q fever identified in Coxiella burnetii by immunoproteomic and protein microarray approaches","volume":"12","author":"Xiong","year":"2012","journal-title":"BMC Microbiol"},{"key":"10.1016\/j.vaccine.2023.04.012_b0170","first-page":"1580","article-title":"Identification of Coxiella burnetii CD8+ T-cell epitopes and delivery by attenuated listeria monocytogenes as a vaccine vector in a C57BL\/6 mouse model","volume":"215","author":"Xiong","year":"2017","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2023.04.012_b0175","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1196\/annals.1355.021","article-title":"Protective immunity against Q fever induced with a recombinant P1 antigen fused with HspB of Coxiella burnetii","volume":"1063","author":"Li","year":"2005","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.vaccine.2023.04.012_b0180","doi-asserted-by":"crossref","first-page":"e1004013","DOI":"10.1371\/journal.ppat.1004013","article-title":"Identification of OmpA, a Coxiella burnetii protein involved in host cell invasion, by multi-phenotypic high-content screening","volume":"10","author":"Martinez","year":"2014","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.vaccine.2023.04.012_b0185","article-title":"Identification of CD4+ T cell epitopes in C. burnetii antigens targeted by antibody responses","volume":"6","author":"Chen","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.vaccine.2023.04.012_b0190","series-title":"The identification of immune-reactive proteins recognised in response to Coxiella burnetii infection","author":"Bewley","year":"2015"},{"key":"10.1016\/j.vaccine.2023.04.012_b0195","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1111\/j.1574-6968.2010.02072.x","article-title":"Coxiella burnetii type IVB secretion system region I genes are expressed early during the infection of host cells","volume":"311","author":"Morgan","year":"2010","journal-title":"FEMS Microbiol Lett"},{"key":"10.1016\/j.vaccine.2023.04.012_b0200","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1146\/annurev.biochem.71.110601.135414","article-title":"Lipopolysaccharide endotoxins","volume":"71","author":"Raetz","year":"2002","journal-title":"Annu Rev Biochem"},{"key":"10.1016\/j.vaccine.2023.04.012_b0205","first-page":"21","article-title":"T cell immunity to bacterial pathogens: mechanisms of immune control and bacterial evasion","author":"Shepherd","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.vaccine.2023.04.012_b0210","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1038\/s41590-021-01122-w","article-title":"The T cell immune response against SARS-CoV-2","volume":"23","author":"Moss","year":"2022","journal-title":"Nat Immunol"},{"key":"10.1016\/j.vaccine.2023.04.012_b0215","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.3389\/fimmu.2019.01678","article-title":"Identification of protective CD8 T cell responses in a mouse model of Zika virus infection","volume":"10","author":"Hassert","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2023.04.012_b0220","doi-asserted-by":"crossref","first-page":"5716","DOI":"10.1038\/s41598-020-61730-8","article-title":"Modification of Adenovirus vaccine vector-induced immune responses by expression of a signalling molecule","volume":"10","author":"Rollier","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.vaccine.2023.04.012_b0225","doi-asserted-by":"crossref","first-page":"3019","DOI":"10.1128\/IAI.00101-10","article-title":"Role of CD4+ and CD8+ T cells in clearance of primary pulmonary infection with Coxiella burnetii","volume":"78","author":"Read","year":"2010","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2023.04.012_b0230","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1111\/j.1749-6632.1995.tb44436.x","article-title":"Potential alterations in immunogenicity by combining or simultaneously administering vaccine components","volume":"754","author":"Insel","year":"1995","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.vaccine.2023.04.012_b0235","doi-asserted-by":"crossref","first-page":"5513","DOI":"10.1016\/j.vaccine.2010.06.026","article-title":"Glycoconjugate vaccines and immune interference: a review","volume":"28","author":"Dagan","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2023.04.012_b0240","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1016\/S0140-6736(08)61591-3","article-title":"Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial","volume":"372","author":"Buchbinder","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2023.04.012_b0245","doi-asserted-by":"crossref","first-page":"5502","DOI":"10.1128\/JVI.03574-13","article-title":"Combined adenovirus vector and hepatitis C virus envelope protein prime-boost regimen elicits T cell and neutralizing antibody immune responses","volume":"88","author":"Chmielewska","year":"2014","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2023.04.012_b0250","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1586\/erv.09.29","article-title":"Strategies to overcome host immunity to adenovirus vectors in vaccine development","volume":"8","author":"Thacker","year":"2009","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2023.04.012_b0255","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1038\/s41541-020-00240-0","article-title":"Optimising T cell (re)boosting strategies for adenoviral and modified vaccinia Ankara vaccine regimens in humans","volume":"5","author":"Capone","year":"2020","journal-title":"npj Vaccines"},{"key":"10.1016\/j.vaccine.2023.04.012_b0260","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1016\/S0140-6736(21)02717-3","article-title":"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial","volume":"398","author":"Munro","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2023.04.012_b0265","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/s41570-020-00244-3","article-title":"Natural and synthetic carbohydrate-based vaccine adjuvants and their mechanisms of action","volume":"5","author":"Pifferi","year":"2021","journal-title":"Nat Rev Chem"},{"key":"10.1016\/j.vaccine.2023.04.012_b0270","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1084\/jem.155.3.666","article-title":"Requirement for three signals in \u201cT-independent\u201d (lipopolysaccharide-induced) as well as in T-dependent B cell responses","volume":"155","author":"Zubler","year":"1982","journal-title":"J Exp Med"},{"key":"10.1016\/j.vaccine.2023.04.012_b0275","first-page":"23","article-title":"Protein carriers for glycoconjugate vaccines: history, selection criteria, characterization and new trends","author":"Micoli","year":"2018","journal-title":"Molecules"},{"key":"10.1016\/j.vaccine.2023.04.012_b0280","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1080\/14760584.2021.1984889","article-title":"Recent advances in lipopolysaccharide-based glycoconjugate vaccines","volume":"20","author":"Zhu","year":"2021","journal-title":"Expert Rev Vaccines"},{"issue":"Suppl. 5","key":"10.1016\/j.vaccine.2023.04.012_b0285","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1111\/j.1469-0691.2012.03943.x","article-title":"A century of pneumococcal vaccination research in humans","volume":"18","author":"Grabenstein","year":"2012","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.vaccine.2023.04.012_b0290","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1002\/(SICI)1096-9888(199602)31:2<138::AID-JMS263>3.0.CO;2-Y","article-title":"Acid and base hydrolysis of lipid A from Enterobacter agglomerans as monitored by electrospray ionization mass spectrometry: pertinence to detoxification mechanisms","volume":"31","author":"Wang","year":"1996","journal-title":"J Mass Spectrom"},{"key":"10.1016\/j.vaccine.2023.04.012_b0295","doi-asserted-by":"crossref","first-page":"4450","DOI":"10.1128\/iai.59.12.4450-4458.1991","article-title":"Preparation, characterization, and immunogenicity of conjugates composed of the O-specific polysaccharide of Shigella dysenteriae type 1 (Shiga\u2019s bacillus) bound to tetanus toxoid","volume":"59","author":"Chu","year":"1991","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2023.04.012_b0300","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.ab.2012.10.038","article-title":"A scalable method for O-antigen purification applied to various Salmonella serovars","volume":"434","author":"Micoli","year":"2013","journal-title":"Anal Biochem"},{"key":"10.1016\/j.vaccine.2023.04.012_b0305","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/S1473-3099(20)30488-6","article-title":"Safety and immunogenicity of a synthetic carbohydrate conjugate vaccine against Shigella flexneri 2a in healthy adult volunteers: a phase 1, dose-escalating, single-blind, randomised, placebo-controlled study","volume":"21","author":"Cohen","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2023.04.012_b0310","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1111\/j.1749-6632.2003.tb07419.x","article-title":"Studies on the immunological role of virenose and dihydrohydroxystreptose present in the Coxiella burnetii phase I lipopolysaccharide","volume":"990","author":"Slab\u00e1","year":"2003","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.vaccine.2023.04.012_b0315","doi-asserted-by":"crossref","first-page":"3822","DOI":"10.1128\/JVI.02568-07","article-title":"Single-dose protection against Plasmodium berghei by a simian adenovirus vector using a human cytomegalovirus promoter containing intron A","volume":"82","author":"Sridhar","year":"2008","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2023.04.012_b0320","first-page":"83","article-title":"Bacterial lipopolysaccharides extraction with phenol-water and further applications of the procedure","volume":"5","author":"Westphal","year":"1965","journal-title":"Methods Carbohydr Chem"},{"key":"10.1016\/j.vaccine.2023.04.012_b0325","first-page":"3","article-title":"Extraction, purification and characterization of lipopolysaccharide from Escherichia coli and Salmonella typhi Avicenna","volume":"3","author":"Rezania","year":"2011","journal-title":"J Med Biotechnol"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X2300395X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X2300395X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T11:25:59Z","timestamp":1759404359000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X2300395X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":65,"journal-issue":{"issue":"19","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["S0264410X2300395X"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2023.04.012","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunisation with purified Coxiella burnetii phase I lipopolysaccharide confers partial protection in mice independently of co-administered adenovirus vectored vaccines","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2023.04.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}